BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 31977539)

  • 1. CHA2DS2-VASc and SAMe-TT2R2 scores as predictors of recurrence for nonvalvular atrial fibrillation patients on vitamin K antagonists after radiofrequency catheter ablation.
    Zhao J; Zhou D; Chen M; Zhuo C; Lin Z; Zheng L; Wang Q
    J Cardiovasc Med (Hagerstown); 2020 Mar; 21(3):200-208. PubMed ID: 31977539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHADS2 and CHA2DS2-VASc scores as predictors of left atrial ablation outcomes for paroxysmal atrial fibrillation.
    Letsas KP; Efremidis M; Giannopoulos G; Deftereos S; Lioni L; Korantzopoulos P; Vlachos K; Xydonas S; Kossyvakis C; Sideris A
    Europace; 2014 Feb; 16(2):202-7. PubMed ID: 23813452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective 'Real-world' Inception Cohort Study.
    Roldán V; Cancio S; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Am J Med; 2015 Nov; 128(11):1237-43. PubMed ID: 26087049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler M; Day JD; Weiss JP; Osborn JS; Muhlestein JB; Anderson JL; Mallender C; Bunch TJ
    Heart Rhythm; 2015 Apr; 12(4):681-6. PubMed ID: 25546809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of CHADS2, R2CHADS2, and CHA2DS2-VASc scores for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry.
    Kornej J; Hindricks G; Kosiuk J; Arya A; Sommer P; Husser D; Rolf S; Richter S; Huo Y; Piorkowski C; Bollmann A
    Circ Arrhythm Electrophysiol; 2014 Apr; 7(2):281-7. PubMed ID: 24610790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry.
    Kornej J; Hindricks G; Kosiuk J; Arya A; Sommer P; Husser D; Rolf S; Richter S; Piorkowski C; Gaspar T; Lip GY; Bollmann A
    Circ Arrhythm Electrophysiol; 2013 Oct; 6(5):868-74. PubMed ID: 24047706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHA
    Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Marín F
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28729407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients.
    Winkle RA; Mead RH; Engel G; Kong MH; Patrawala RA
    Europace; 2014 Feb; 16(2):195-201. PubMed ID: 24036378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores.
    Proietti M; Rivera-Caravaca JM; Esteve-Pastor MA; Marín F; Lip GYH
    Thromb Haemost; 2021 Aug; 121(8):1107-1114. PubMed ID: 33296920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists.
    Abumuaileq RR; Abu-Assi E; Raposeiras-Roubin S; López-López A; Redondo-Diéguez A; Álvarez-Iglesias D; Rodríguez-Mañero M; Peña-Gil C; González-Juanatey JR
    Europace; 2015 May; 17(5):711-7. PubMed ID: 25662984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the mean time in the therapeutic INR range and the SAME-TT2R2 score in patients with atrial fibrillation and cognitive impairment.
    Gorzelak-Pabiś P; Zyzak S; Krewko Ł; Broncel M
    Pol Arch Med Wewn; 2016 Aug; 126(7-8):494-501. PubMed ID: 27511466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHA2DS2-VASc score and fibrinogen concentration in patients with atrial fibrillation.
    Semczuk-Kaczmarek K; Płatek AE; Ryś A; Adamowicz J; Legosz P; Kotkowski M; Dudzik-Płocica A; Gorko D; Szymański FM; Filipiak KJ
    Adv Clin Exp Med; 2019 Nov; 28(11):1451-1457. PubMed ID: 31596555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation.
    Noseworthy PA; Yao X; Deshmukh AJ; Van Houten H; Sangaralingham LR; Siontis KC; Piccini JP; Asirvatham SJ; Friedman PA; Packer DL; Gersh BJ; Shah ND
    J Am Heart Assoc; 2015 Nov; 4(11):. PubMed ID: 26541393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C
    Özmen G; Koca F
    Kardiologiia; 2023 Jun; 63(6):52-60. PubMed ID: 37470734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Use vs Discontinuation of Oral Anticoagulation After Pulmonary Vein Isolation in Patients With Atrial Fibrillation.
    Själander S; Holmqvist F; Smith JG; Platonov PG; Kesek M; Svensson PJ; Blomström-Lundqvist C; Tabrizi F; Tapanainen J; Poci D; Jönsson A; Själander A
    JAMA Cardiol; 2017 Feb; 2(2):146-152. PubMed ID: 27893055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
    Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial fibrillation type and renal dysfunction as important predictors of left atrial thrombus.
    Kapłon-Cieślicka A; Budnik M; Gawałko M; Peller M; Gorczyca I; Michalska A; Babiarz A; Bodys A; Uliński R; Żochowski M; Scisło P; Kochanowski J; Filipiak KJ; Opolski G
    Heart; 2019 Sep; 105(17):1310-1315. PubMed ID: 31040170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).
    Lip GYH; Al-Saady N; Jin J; Sun M; Melino M; Winters SM; Zamoryakhin D; Goette A
    Am J Cardiol; 2017 Sep; 120(5):792-796. PubMed ID: 28709650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
    Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation.
    Yao X; Abraham NS; Alexander GC; Crown W; Montori VM; Sangaralingham LR; Gersh BJ; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26908412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.